nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—bone cancer—thyroid cancer	0.217	0.399	CtDrD
Methotrexate—germ cell cancer—thyroid cancer	0.173	0.317	CtDrD
Methotrexate—lung cancer—thyroid cancer	0.155	0.285	CtDrD
Methotrexate—ABCC1—Vandetanib—thyroid cancer	0.0387	0.141	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—thyroid cancer	0.0367	0.134	CbGbCtD
Methotrexate—ABCC4—Sorafenib—thyroid cancer	0.029	0.106	CbGbCtD
Methotrexate—ABCC1—Epirubicin—thyroid cancer	0.0266	0.0972	CbGbCtD
Methotrexate—ABCG2—Vandetanib—thyroid cancer	0.0259	0.0946	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—thyroid cancer	0.0231	0.0842	CbGbCtD
Methotrexate—ALB—Vandetanib—thyroid cancer	0.0179	0.0652	CbGbCtD
Methotrexate—ABCC2—Sorafenib—thyroid cancer	0.0173	0.063	CbGbCtD
Methotrexate—ABCG2—Sorafenib—thyroid cancer	0.0156	0.057	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—thyroid cancer	0.0142	0.0517	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—thyroid cancer	0.0105	0.0383	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—thyroid cancer	0.00948	0.0346	CbGbCtD
Methotrexate—ABCB1—Sorafenib—thyroid cancer	0.00563	0.0206	CbGbCtD
Methotrexate—ABCB1—Doxorubicin—thyroid cancer	0.00342	0.0125	CbGbCtD
Methotrexate—FOLR1—saliva-secreting gland—thyroid cancer	0.00182	0.0475	CbGeAlD
Methotrexate—FOLR1—trachea—thyroid cancer	0.00141	0.0366	CbGeAlD
Methotrexate—GGH—saliva-secreting gland—thyroid cancer	0.00121	0.0316	CbGeAlD
Methotrexate—FOLR1—thyroid gland—thyroid cancer	0.00111	0.029	CbGeAlD
Methotrexate—FPGS—saliva-secreting gland—thyroid cancer	0.00107	0.0277	CbGeAlD
Methotrexate—FOLR1—head—thyroid cancer	0.000988	0.0257	CbGeAlD
Methotrexate—MTHFR—neck—thyroid cancer	0.000983	0.0256	CbGeAlD
Methotrexate—SLC19A1—thyroid gland—thyroid cancer	0.000977	0.0254	CbGeAlD
Methotrexate—GGH—trachea—thyroid cancer	0.000936	0.0243	CbGeAlD
Methotrexate—TYMS—Erlotinib—Vandetanib—thyroid cancer	0.000873	0.449	CbGdCrCtD
Methotrexate—SLC19A1—head—thyroid cancer	0.000866	0.0225	CbGeAlD
Methotrexate—PGD—neck—thyroid cancer	0.000853	0.0222	CbGeAlD
Methotrexate—SLCO4C1—trachea—thyroid cancer	0.00083	0.0216	CbGeAlD
Methotrexate—FPGS—trachea—thyroid cancer	0.000822	0.0214	CbGeAlD
Methotrexate—SLC46A1—thyroid gland—thyroid cancer	0.000752	0.0196	CbGeAlD
Methotrexate—GGH—thyroid gland—thyroid cancer	0.00074	0.0193	CbGeAlD
Methotrexate—DHFR—saliva-secreting gland—thyroid cancer	0.000692	0.018	CbGeAlD
Methotrexate—SLC46A1—head—thyroid cancer	0.000667	0.0174	CbGeAlD
Methotrexate—PGD—saliva-secreting gland—thyroid cancer	0.000666	0.0173	CbGeAlD
Methotrexate—GGH—head—thyroid cancer	0.000657	0.0171	CbGeAlD
Methotrexate—FPGS—thyroid gland—thyroid cancer	0.000651	0.0169	CbGeAlD
Methotrexate—ATIC—thyroid gland—thyroid cancer	0.000629	0.0164	CbGeAlD
Methotrexate—SLC19A1—lymph node—thyroid cancer	0.000607	0.0158	CbGeAlD
Methotrexate—FPGS—head—thyroid cancer	0.000577	0.015	CbGeAlD
Methotrexate—TYMS—Afatinib—Vandetanib—thyroid cancer	0.000571	0.294	CbGdCrCtD
Methotrexate—ABCC10—saliva-secreting gland—thyroid cancer	0.000571	0.0149	CbGeAlD
Methotrexate—ATIC—head—thyroid cancer	0.000558	0.0145	CbGeAlD
Methotrexate—DHFR—trachea—thyroid cancer	0.000534	0.0139	CbGeAlD
Methotrexate—SLCO1C1—thyroid gland—thyroid cancer	0.000523	0.0136	CbGeAlD
Methotrexate—PGD—trachea—thyroid cancer	0.000514	0.0134	CbGeAlD
Methotrexate—TYMS—Gefitinib—Vandetanib—thyroid cancer	0.000499	0.257	CbGdCrCtD
Methotrexate—MTHFR—thyroid gland—thyroid cancer	0.000468	0.0122	CbGeAlD
Methotrexate—SLC46A1—lymph node—thyroid cancer	0.000467	0.0122	CbGeAlD
Methotrexate—SLCO1C1—head—thyroid cancer	0.000464	0.0121	CbGeAlD
Methotrexate—SLCO3A1—thyroid gland—thyroid cancer	0.00046	0.012	CbGeAlD
Methotrexate—GGH—lymph node—thyroid cancer	0.00046	0.012	CbGeAlD
Methotrexate—AOX1—trachea—thyroid cancer	0.000452	0.0118	CbGeAlD
Methotrexate—ABCC10—trachea—thyroid cancer	0.00044	0.0115	CbGeAlD
Methotrexate—TYMS—thyroid gland—thyroid cancer	0.000427	0.0111	CbGeAlD
Methotrexate—DHFR—thyroid gland—thyroid cancer	0.000423	0.011	CbGeAlD
Methotrexate—MTHFR—head—thyroid cancer	0.000415	0.0108	CbGeAlD
Methotrexate—SLCO3A1—head—thyroid cancer	0.000408	0.0106	CbGeAlD
Methotrexate—PGD—thyroid gland—thyroid cancer	0.000406	0.0106	CbGeAlD
Methotrexate—FPGS—lymph node—thyroid cancer	0.000404	0.0105	CbGeAlD
Methotrexate—ATIC—lymph node—thyroid cancer	0.000391	0.0102	CbGeAlD
Methotrexate—SLC16A1—thyroid gland—thyroid cancer	0.000379	0.00987	CbGeAlD
Methotrexate—TYMS—head—thyroid cancer	0.000379	0.00985	CbGeAlD
Methotrexate—DHFR—head—thyroid cancer	0.000375	0.00975	CbGeAlD
Methotrexate—PGD—head—thyroid cancer	0.00036	0.00938	CbGeAlD
Methotrexate—AOX1—thyroid gland—thyroid cancer	0.000358	0.00931	CbGeAlD
Methotrexate—ABCC3—thyroid gland—thyroid cancer	0.00035	0.00911	CbGeAlD
Methotrexate—ABCC10—thyroid gland—thyroid cancer	0.000348	0.00906	CbGeAlD
Methotrexate—SLC16A1—head—thyroid cancer	0.000336	0.00875	CbGeAlD
Methotrexate—ABCG2—saliva-secreting gland—thyroid cancer	0.000334	0.0087	CbGeAlD
Methotrexate—SLCO1C1—lymph node—thyroid cancer	0.000325	0.00846	CbGeAlD
Methotrexate—ABCC1—trachea—thyroid cancer	0.000311	0.0081	CbGeAlD
Methotrexate—ABCC3—head—thyroid cancer	0.000311	0.00808	CbGeAlD
Methotrexate—MTHFR—lymph node—thyroid cancer	0.000291	0.00756	CbGeAlD
Methotrexate—ABCC4—thyroid gland—thyroid cancer	0.000289	0.00752	CbGeAlD
Methotrexate—SLCO3A1—lymph node—thyroid cancer	0.000286	0.00744	CbGeAlD
Methotrexate—SLCO1A2—head—thyroid cancer	0.000266	0.00693	CbGeAlD
Methotrexate—TYMS—lymph node—thyroid cancer	0.000265	0.0069	CbGeAlD
Methotrexate—DHFR—lymph node—thyroid cancer	0.000262	0.00683	CbGeAlD
Methotrexate—ABCC4—head—thyroid cancer	0.000256	0.00667	CbGeAlD
Methotrexate—SLC22A8—head—thyroid cancer	0.000254	0.00662	CbGeAlD
Methotrexate—PGD—lymph node—thyroid cancer	0.000252	0.00657	CbGeAlD
Methotrexate—ABCC1—thyroid gland—thyroid cancer	0.000246	0.00641	CbGeAlD
Methotrexate—SLC16A1—lymph node—thyroid cancer	0.000236	0.00613	CbGeAlD
Methotrexate—AOX1—lymph node—thyroid cancer	0.000222	0.00578	CbGeAlD
Methotrexate—ABCC3—lymph node—thyroid cancer	0.000217	0.00566	CbGeAlD
Methotrexate—ABCC10—lymph node—thyroid cancer	0.000216	0.00563	CbGeAlD
Methotrexate—ABCG2—thyroid gland—thyroid cancer	0.000204	0.00531	CbGeAlD
Methotrexate—ALB—lymph node—thyroid cancer	0.000185	0.00482	CbGeAlD
Methotrexate—ABCC4—lymph node—thyroid cancer	0.000179	0.00467	CbGeAlD
Methotrexate—ABCC2—lymph node—thyroid cancer	0.000174	0.00452	CbGeAlD
Methotrexate—ABCC1—lymph node—thyroid cancer	0.000153	0.00398	CbGeAlD
Methotrexate—ABCB1—trachea—thyroid cancer	0.000127	0.00331	CbGeAlD
Methotrexate—ABCG2—lymph node—thyroid cancer	0.000127	0.0033	CbGeAlD
Methotrexate—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000109	0.00113	CcSEcCtD
Methotrexate—Melaena—Doxorubicin—thyroid cancer	0.000109	0.00113	CcSEcCtD
Methotrexate—Rash—Vandetanib—thyroid cancer	0.000109	0.00113	CcSEcCtD
Methotrexate—Dermatitis—Vandetanib—thyroid cancer	0.000109	0.00113	CcSEcCtD
Methotrexate—Headache—Vandetanib—thyroid cancer	0.000108	0.00112	CcSEcCtD
Methotrexate—Cystitis—Doxorubicin—thyroid cancer	0.000108	0.00112	CcSEcCtD
Methotrexate—Pulmonary oedema—Epirubicin—thyroid cancer	0.000107	0.00111	CcSEcCtD
Methotrexate—Skin exfoliation—Doxorubicin—thyroid cancer	0.000106	0.00111	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000106	0.0011	CcSEcCtD
Methotrexate—Vaginal infection—Doxorubicin—thyroid cancer	0.000105	0.00109	CcSEcCtD
Methotrexate—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000105	0.00109	CcSEcCtD
Methotrexate—Sepsis—Epirubicin—thyroid cancer	0.000105	0.00109	CcSEcCtD
Methotrexate—Dyspnoea—Sorafenib—thyroid cancer	0.000104	0.00108	CcSEcCtD
Methotrexate—Lymphadenopathy—Epirubicin—thyroid cancer	0.000102	0.00106	CcSEcCtD
Methotrexate—Nausea—Vandetanib—thyroid cancer	0.000102	0.00106	CcSEcCtD
Methotrexate—Dyspepsia—Sorafenib—thyroid cancer	0.000102	0.00106	CcSEcCtD
Methotrexate—Coma—Doxorubicin—thyroid cancer	0.000102	0.00106	CcSEcCtD
Methotrexate—Decreased appetite—Sorafenib—thyroid cancer	0.000101	0.00105	CcSEcCtD
Methotrexate—Thrombophlebitis—Epirubicin—thyroid cancer	0.000101	0.00105	CcSEcCtD
Methotrexate—Bladder pain—Doxorubicin—thyroid cancer	0.000101	0.00105	CcSEcCtD
Methotrexate—Ecchymosis—Doxorubicin—thyroid cancer	0.000101	0.00105	CcSEcCtD
Methotrexate—Neoplasm—Doxorubicin—thyroid cancer	0.000101	0.00105	CcSEcCtD
Methotrexate—Mouth ulceration—Doxorubicin—thyroid cancer	0.000101	0.00105	CcSEcCtD
Methotrexate—ABCB1—thyroid gland—thyroid cancer	0.000101	0.00262	CbGeAlD
Methotrexate—Diabetes mellitus—Epirubicin—thyroid cancer	0.000101	0.00104	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0001	0.00104	CcSEcCtD
Methotrexate—Fatigue—Sorafenib—thyroid cancer	0.0001	0.00104	CcSEcCtD
Methotrexate—Photosensitivity—Epirubicin—thyroid cancer	9.96e-05	0.00103	CcSEcCtD
Methotrexate—Pain—Sorafenib—thyroid cancer	9.94e-05	0.00103	CcSEcCtD
Methotrexate—Pulmonary oedema—Doxorubicin—thyroid cancer	9.92e-05	0.00103	CcSEcCtD
Methotrexate—Hepatic failure—Epirubicin—thyroid cancer	9.73e-05	0.00101	CcSEcCtD
Methotrexate—Sepsis—Doxorubicin—thyroid cancer	9.67e-05	0.00101	CcSEcCtD
Methotrexate—Gastrointestinal pain—Sorafenib—thyroid cancer	9.51e-05	0.000988	CcSEcCtD
Methotrexate—Lymphadenopathy—Doxorubicin—thyroid cancer	9.48e-05	0.000985	CcSEcCtD
Methotrexate—Renal failure acute—Epirubicin—thyroid cancer	9.47e-05	0.000984	CcSEcCtD
Methotrexate—Thrombophlebitis—Doxorubicin—thyroid cancer	9.35e-05	0.000971	CcSEcCtD
Methotrexate—Diabetes mellitus—Doxorubicin—thyroid cancer	9.3e-05	0.000967	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Epirubicin—thyroid cancer	9.27e-05	0.000963	CcSEcCtD
Methotrexate—Urticaria—Sorafenib—thyroid cancer	9.24e-05	0.00096	CcSEcCtD
Methotrexate—Photosensitivity—Doxorubicin—thyroid cancer	9.21e-05	0.000957	CcSEcCtD
Methotrexate—Abdominal pain—Sorafenib—thyroid cancer	9.19e-05	0.000955	CcSEcCtD
Methotrexate—Body temperature increased—Sorafenib—thyroid cancer	9.19e-05	0.000955	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Epirubicin—thyroid cancer	9.03e-05	0.000939	CcSEcCtD
Methotrexate—Hepatic failure—Doxorubicin—thyroid cancer	9e-05	0.000935	CcSEcCtD
Methotrexate—ABCB1—head—thyroid cancer	8.92e-05	0.00232	CbGeAlD
Methotrexate—Cerebrovascular accident—Epirubicin—thyroid cancer	8.92e-05	0.000927	CcSEcCtD
Methotrexate—Lethargy—Epirubicin—thyroid cancer	8.92e-05	0.000927	CcSEcCtD
Methotrexate—Renal failure acute—Doxorubicin—thyroid cancer	8.76e-05	0.000911	CcSEcCtD
Methotrexate—Osteoarthritis—Epirubicin—thyroid cancer	8.74e-05	0.000909	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Doxorubicin—thyroid cancer	8.57e-05	0.000891	CcSEcCtD
Methotrexate—Hypersensitivity—Sorafenib—thyroid cancer	8.57e-05	0.00089	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Doxorubicin—thyroid cancer	8.36e-05	0.000869	CcSEcCtD
Methotrexate—Asthenia—Sorafenib—thyroid cancer	8.34e-05	0.000867	CcSEcCtD
Methotrexate—Mood swings—Epirubicin—thyroid cancer	8.28e-05	0.000861	CcSEcCtD
Methotrexate—Cerebrovascular accident—Doxorubicin—thyroid cancer	8.26e-05	0.000858	CcSEcCtD
Methotrexate—Lethargy—Doxorubicin—thyroid cancer	8.26e-05	0.000858	CcSEcCtD
Methotrexate—Pruritus—Sorafenib—thyroid cancer	8.23e-05	0.000855	CcSEcCtD
Methotrexate—Ataxia—Epirubicin—thyroid cancer	8.22e-05	0.000854	CcSEcCtD
Methotrexate—Osteoarthritis—Doxorubicin—thyroid cancer	8.09e-05	0.000841	CcSEcCtD
Methotrexate—Liver function test abnormal—Epirubicin—thyroid cancer	8.07e-05	0.000839	CcSEcCtD
Methotrexate—Diarrhoea—Sorafenib—thyroid cancer	7.96e-05	0.000827	CcSEcCtD
Methotrexate—Breast disorder—Epirubicin—thyroid cancer	7.9e-05	0.000821	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	7.87e-05	0.000818	CcSEcCtD
Methotrexate—Dizziness—Sorafenib—thyroid cancer	7.69e-05	0.000799	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—thyroid cancer	7.66e-05	0.000796	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—thyroid cancer	7.61e-05	0.000791	CcSEcCtD
Methotrexate—Asthma—Epirubicin—thyroid cancer	7.56e-05	0.000785	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—thyroid cancer	7.48e-05	0.000778	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—thyroid cancer	7.47e-05	0.000776	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—thyroid cancer	7.41e-05	0.00077	CcSEcCtD
Methotrexate—Vomiting—Sorafenib—thyroid cancer	7.39e-05	0.000768	CcSEcCtD
Methotrexate—Rash—Sorafenib—thyroid cancer	7.33e-05	0.000762	CcSEcCtD
Methotrexate—Dermatitis—Sorafenib—thyroid cancer	7.32e-05	0.000761	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—thyroid cancer	7.31e-05	0.00076	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	7.28e-05	0.000757	CcSEcCtD
Methotrexate—Headache—Sorafenib—thyroid cancer	7.28e-05	0.000757	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—thyroid cancer	7.18e-05	0.000746	CcSEcCtD
Methotrexate—Neutropenia—Epirubicin—thyroid cancer	7.07e-05	0.000734	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—thyroid cancer	7.07e-05	0.000734	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—thyroid cancer	7.02e-05	0.00073	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—thyroid cancer	6.99e-05	0.000727	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—thyroid cancer	6.92e-05	0.000719	CcSEcCtD
Methotrexate—Nausea—Sorafenib—thyroid cancer	6.91e-05	0.000718	CcSEcCtD
Methotrexate—Photosensitivity reaction—Epirubicin—thyroid cancer	6.9e-05	0.000717	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—thyroid cancer	6.86e-05	0.000712	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—thyroid cancer	6.78e-05	0.000704	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—thyroid cancer	6.74e-05	0.0007	CcSEcCtD
Methotrexate—Infestation—Epirubicin—thyroid cancer	6.74e-05	0.0007	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—thyroid cancer	6.74e-05	0.0007	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	6.68e-05	0.000694	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—thyroid cancer	6.64e-05	0.00069	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—thyroid cancer	6.62e-05	0.000688	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—thyroid cancer	6.57e-05	0.000683	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—thyroid cancer	6.55e-05	0.000681	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—thyroid cancer	6.54e-05	0.000679	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—thyroid cancer	6.54e-05	0.000679	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—thyroid cancer	6.5e-05	0.000675	CcSEcCtD
Methotrexate—Sweating—Epirubicin—thyroid cancer	6.46e-05	0.000671	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—thyroid cancer	6.42e-05	0.000668	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—thyroid cancer	6.38e-05	0.000663	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—thyroid cancer	6.37e-05	0.000662	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—thyroid cancer	6.36e-05	0.00066	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—thyroid cancer	6.29e-05	0.000653	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—thyroid cancer	6.27e-05	0.000652	CcSEcCtD
Methotrexate—ABCB1—lymph node—thyroid cancer	6.25e-05	0.00163	CbGeAlD
Methotrexate—Drowsiness—Doxorubicin—thyroid cancer	6.23e-05	0.000648	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—thyroid cancer	6.23e-05	0.000648	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—thyroid cancer	6.23e-05	0.000648	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	6.18e-05	0.000642	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—thyroid cancer	6.13e-05	0.000637	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—thyroid cancer	6.08e-05	0.000632	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—thyroid cancer	6.08e-05	0.000632	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—thyroid cancer	6.06e-05	0.00063	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—thyroid cancer	6.05e-05	0.000629	CcSEcCtD
Methotrexate—Hepatitis—Epirubicin—thyroid cancer	6.05e-05	0.000629	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—thyroid cancer	6e-05	0.000624	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—thyroid cancer	5.98e-05	0.000621	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—thyroid cancer	5.97e-05	0.000621	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—thyroid cancer	5.94e-05	0.000618	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—thyroid cancer	5.93e-05	0.000616	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—thyroid cancer	5.9e-05	0.000613	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—thyroid cancer	5.88e-05	0.000611	CcSEcCtD
Methotrexate—Visual impairment—Epirubicin—thyroid cancer	5.83e-05	0.000606	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—thyroid cancer	5.82e-05	0.000605	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—thyroid cancer	5.72e-05	0.000594	CcSEcCtD
Methotrexate—Eye disorder—Epirubicin—thyroid cancer	5.65e-05	0.000587	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—thyroid cancer	5.64e-05	0.000586	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—thyroid cancer	5.63e-05	0.000585	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—thyroid cancer	5.61e-05	0.000583	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—thyroid cancer	5.6e-05	0.000582	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—thyroid cancer	5.6e-05	0.000582	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—thyroid cancer	5.55e-05	0.000577	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—thyroid cancer	5.53e-05	0.000574	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—thyroid cancer	5.49e-05	0.00057	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—thyroid cancer	5.49e-05	0.00057	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—thyroid cancer	5.46e-05	0.000568	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—thyroid cancer	5.45e-05	0.000566	CcSEcCtD
Methotrexate—Chills—Epirubicin—thyroid cancer	5.43e-05	0.000564	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—thyroid cancer	5.39e-05	0.00056	CcSEcCtD
Methotrexate—Alopecia—Epirubicin—thyroid cancer	5.34e-05	0.000555	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—thyroid cancer	5.3e-05	0.000551	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—thyroid cancer	5.29e-05	0.00055	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—thyroid cancer	5.27e-05	0.000547	CcSEcCtD
Methotrexate—Erythema—Epirubicin—thyroid cancer	5.27e-05	0.000547	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—thyroid cancer	5.23e-05	0.000544	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—thyroid cancer	5.22e-05	0.000542	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—thyroid cancer	5.19e-05	0.00054	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—thyroid cancer	5.16e-05	0.000536	CcSEcCtD
Methotrexate—Back pain—Epirubicin—thyroid cancer	5.09e-05	0.000529	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—thyroid cancer	5.08e-05	0.000528	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—thyroid cancer	5.06e-05	0.000525	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—thyroid cancer	5.04e-05	0.000524	CcSEcCtD
Methotrexate—Chills—Doxorubicin—thyroid cancer	5.02e-05	0.000522	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—thyroid cancer	4.96e-05	0.000516	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—thyroid cancer	4.95e-05	0.000514	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—thyroid cancer	4.9e-05	0.00051	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—thyroid cancer	4.89e-05	0.000508	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—thyroid cancer	4.87e-05	0.000506	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—thyroid cancer	4.87e-05	0.000506	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—thyroid cancer	4.87e-05	0.000506	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—thyroid cancer	4.77e-05	0.000496	CcSEcCtD
Methotrexate—Malaise—Epirubicin—thyroid cancer	4.75e-05	0.000493	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—thyroid cancer	4.73e-05	0.000492	CcSEcCtD
Methotrexate—Leukopenia—Epirubicin—thyroid cancer	4.71e-05	0.00049	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—thyroid cancer	4.71e-05	0.00049	CcSEcCtD
Methotrexate—Cough—Epirubicin—thyroid cancer	4.59e-05	0.000477	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—thyroid cancer	4.59e-05	0.000477	CcSEcCtD
Methotrexate—Convulsion—Epirubicin—thyroid cancer	4.56e-05	0.000474	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—thyroid cancer	4.52e-05	0.00047	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—thyroid cancer	4.5e-05	0.000468	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—thyroid cancer	4.48e-05	0.000466	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—thyroid cancer	4.48e-05	0.000466	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—thyroid cancer	4.48e-05	0.000466	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	4.45e-05	0.000463	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—thyroid cancer	4.43e-05	0.00046	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—thyroid cancer	4.39e-05	0.000457	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—thyroid cancer	4.38e-05	0.000455	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—thyroid cancer	4.36e-05	0.000453	CcSEcCtD
Methotrexate—Confusional state—Epirubicin—thyroid cancer	4.33e-05	0.00045	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—thyroid cancer	4.3e-05	0.000447	CcSEcCtD
Methotrexate—Infection—Epirubicin—thyroid cancer	4.27e-05	0.000444	CcSEcCtD
Methotrexate—Cough—Doxorubicin—thyroid cancer	4.25e-05	0.000442	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—thyroid cancer	4.22e-05	0.000439	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—thyroid cancer	4.21e-05	0.000438	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—thyroid cancer	4.21e-05	0.000437	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—thyroid cancer	4.17e-05	0.000434	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—thyroid cancer	4.15e-05	0.000432	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—thyroid cancer	4.15e-05	0.000431	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—thyroid cancer	4.15e-05	0.000431	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—thyroid cancer	4.15e-05	0.000431	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	4.12e-05	0.000428	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—thyroid cancer	4.1e-05	0.000426	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—thyroid cancer	4.1e-05	0.000426	CcSEcCtD
Methotrexate—Hypotension—Epirubicin—thyroid cancer	4.02e-05	0.000417	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—thyroid cancer	4.01e-05	0.000417	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—thyroid cancer	3.98e-05	0.000413	CcSEcCtD
Methotrexate—Infection—Doxorubicin—thyroid cancer	3.95e-05	0.000411	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—thyroid cancer	3.92e-05	0.000407	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—thyroid cancer	3.9e-05	0.000405	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—thyroid cancer	3.89e-05	0.000405	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—thyroid cancer	3.89e-05	0.000404	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—thyroid cancer	3.86e-05	0.000401	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—thyroid cancer	3.86e-05	0.000401	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—thyroid cancer	3.84e-05	0.000399	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—thyroid cancer	3.83e-05	0.000398	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—thyroid cancer	3.82e-05	0.000397	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—thyroid cancer	3.79e-05	0.000394	CcSEcCtD
Methotrexate—Dyspepsia—Epirubicin—thyroid cancer	3.78e-05	0.000393	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—thyroid cancer	3.74e-05	0.000388	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—thyroid cancer	3.72e-05	0.000386	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—thyroid cancer	3.71e-05	0.000386	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—thyroid cancer	3.7e-05	0.000385	CcSEcCtD
Methotrexate—Pain—Epirubicin—thyroid cancer	3.67e-05	0.000382	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	3.62e-05	0.000376	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—thyroid cancer	3.6e-05	0.000374	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—thyroid cancer	3.57e-05	0.000371	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—thyroid cancer	3.54e-05	0.000368	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—thyroid cancer	3.54e-05	0.000368	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—thyroid cancer	3.53e-05	0.000367	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—thyroid cancer	3.51e-05	0.000365	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—thyroid cancer	3.5e-05	0.000364	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—thyroid cancer	3.46e-05	0.000359	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	3.43e-05	0.000357	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—thyroid cancer	3.43e-05	0.000356	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—thyroid cancer	3.41e-05	0.000355	CcSEcCtD
Methotrexate—Pain—Doxorubicin—thyroid cancer	3.4e-05	0.000353	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—thyroid cancer	3.4e-05	0.000353	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—thyroid cancer	3.4e-05	0.000353	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—thyroid cancer	3.28e-05	0.000341	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—thyroid cancer	3.25e-05	0.000338	CcSEcCtD
Methotrexate—Hypersensitivity—Epirubicin—thyroid cancer	3.17e-05	0.000329	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—thyroid cancer	3.16e-05	0.000328	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—thyroid cancer	3.14e-05	0.000327	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—thyroid cancer	3.14e-05	0.000327	CcSEcCtD
Methotrexate—Asthenia—Epirubicin—thyroid cancer	3.08e-05	0.00032	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—thyroid cancer	3.04e-05	0.000316	CcSEcCtD
Methotrexate—Diarrhoea—Epirubicin—thyroid cancer	2.94e-05	0.000306	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—thyroid cancer	2.93e-05	0.000304	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—thyroid cancer	2.85e-05	0.000296	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—thyroid cancer	2.84e-05	0.000295	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—thyroid cancer	2.81e-05	0.000292	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—thyroid cancer	2.73e-05	0.000284	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—thyroid cancer	2.72e-05	0.000283	CcSEcCtD
Methotrexate—Rash—Epirubicin—thyroid cancer	2.71e-05	0.000282	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—thyroid cancer	2.71e-05	0.000281	CcSEcCtD
Methotrexate—Headache—Epirubicin—thyroid cancer	2.69e-05	0.00028	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—thyroid cancer	2.63e-05	0.000273	CcSEcCtD
Methotrexate—Nausea—Epirubicin—thyroid cancer	2.55e-05	0.000265	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—thyroid cancer	2.53e-05	0.000263	CcSEcCtD
Methotrexate—Rash—Doxorubicin—thyroid cancer	2.51e-05	0.000261	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—thyroid cancer	2.5e-05	0.00026	CcSEcCtD
Methotrexate—Headache—Doxorubicin—thyroid cancer	2.49e-05	0.000259	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—thyroid cancer	2.36e-05	0.000245	CcSEcCtD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.81e-05	0.00041	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.8e-05	0.000409	CbGpPWpGaD
Methotrexate—PGD—Disease—BRAF—thyroid cancer	1.79e-05	0.000406	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PRKAR1A—thyroid cancer	1.79e-05	0.000406	CbGpPWpGaD
Methotrexate—FPGS—Disease—PTEN—thyroid cancer	1.77e-05	0.000401	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.75e-05	0.000396	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PTEN—thyroid cancer	1.74e-05	0.000395	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.73e-05	0.000391	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.73e-05	0.000391	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—SLC5A5—thyroid cancer	1.7e-05	0.000386	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTGS2—thyroid cancer	1.7e-05	0.000385	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTGS2—thyroid cancer	1.7e-05	0.000385	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PRKAR1A—thyroid cancer	1.69e-05	0.000384	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PPARG—thyroid cancer	1.68e-05	0.000381	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.67e-05	0.000379	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CCND1—thyroid cancer	1.67e-05	0.000378	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRG1—thyroid cancer	1.66e-05	0.000376	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MINPP1—thyroid cancer	1.65e-05	0.000375	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TPR—thyroid cancer	1.64e-05	0.000372	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.64e-05	0.000372	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—thyroid cancer	1.63e-05	0.00037	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRG1—thyroid cancer	1.62e-05	0.000368	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.62e-05	0.000368	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PRKAR1A—thyroid cancer	1.62e-05	0.000366	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—RXRA—thyroid cancer	1.61e-05	0.000365	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NDUFA13—thyroid cancer	1.6e-05	0.000364	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—KRAS—thyroid cancer	1.6e-05	0.000362	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTGS2—thyroid cancer	1.58e-05	0.000358	CbGpPWpGaD
Methotrexate—FPGS—Disease—NRAS—thyroid cancer	1.58e-05	0.000358	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—RXRA—thyroid cancer	1.57e-05	0.000356	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—SLC5A5—thyroid cancer	1.55e-05	0.000351	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PPARG—thyroid cancer	1.54e-05	0.000349	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TPR—thyroid cancer	1.54e-05	0.000348	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.52e-05	0.000344	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PRKAR1A—thyroid cancer	1.51e-05	0.000342	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CHST14—thyroid cancer	1.51e-05	0.000342	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CCND1—thyroid cancer	1.49e-05	0.000338	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TERT—thyroid cancer	1.49e-05	0.000338	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	1.49e-05	0.000338	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	1.49e-05	0.000338	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—SLC5A5—thyroid cancer	1.48e-05	0.000336	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTEN—thyroid cancer	1.48e-05	0.000336	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTEN—thyroid cancer	1.48e-05	0.000336	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRG1—thyroid cancer	1.48e-05	0.000335	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.47e-05	0.000332	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.46e-05	0.000332	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CCND1—thyroid cancer	1.46e-05	0.00033	CbGpPWpGaD
Methotrexate—AOX1—Disease—TERT—thyroid cancer	1.46e-05	0.00033	CbGpPWpGaD
Methotrexate—PGD—Disease—PTGS2—thyroid cancer	1.45e-05	0.000328	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MEN1—thyroid cancer	1.44e-05	0.000327	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—RXRA—thyroid cancer	1.43e-05	0.000324	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TPR—thyroid cancer	1.43e-05	0.000324	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HIF1A—thyroid cancer	1.43e-05	0.000323	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PRKAR1A—thyroid cancer	1.41e-05	0.000319	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NDUFA13—thyroid cancer	1.41e-05	0.000319	CbGpPWpGaD
Methotrexate—AOX1—Disease—HIF1A—thyroid cancer	1.39e-05	0.000316	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTEN—thyroid cancer	1.38e-05	0.000312	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—SLC5A5—thyroid cancer	1.36e-05	0.000309	CbGpPWpGaD
Methotrexate—FPGS—Disease—KRAS—thyroid cancer	1.36e-05	0.000308	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—HRAS—thyroid cancer	1.36e-05	0.000308	CbGpPWpGaD
Methotrexate—DHFR—Disease—TERT—thyroid cancer	1.33e-05	0.0003	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTGS2—thyroid cancer	1.32e-05	0.0003	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CHST14—thyroid cancer	1.32e-05	0.0003	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.31e-05	0.000296	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.31e-05	0.000296	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CCND1—thyroid cancer	1.3e-05	0.000295	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—RXRA—thyroid cancer	1.3e-05	0.000295	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TPR—thyroid cancer	1.29e-05	0.000291	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.29e-05	0.000291	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.28e-05	0.000289	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.27e-05	0.000289	CbGpPWpGaD
Methotrexate—DHFR—Disease—HIF1A—thyroid cancer	1.27e-05	0.000287	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PRKAR1A—thyroid cancer	1.27e-05	0.000287	CbGpPWpGaD
Methotrexate—PGD—Disease—PTEN—thyroid cancer	1.26e-05	0.000286	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—RXRA—thyroid cancer	1.25e-05	0.000283	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NRAS—thyroid cancer	1.24e-05	0.000281	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NRAS—thyroid cancer	1.23e-05	0.000279	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—SLC5A5—thyroid cancer	1.23e-05	0.000278	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TPR—thyroid cancer	1.22e-05	0.000277	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HPGD—thyroid cancer	1.22e-05	0.000276	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—thyroid cancer	1.21e-05	0.000274	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.21e-05	0.000274	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	1.2e-05	0.000273	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—AKT1—thyroid cancer	1.2e-05	0.000272	CbGpPWpGaD
Methotrexate—MTHFR—Disease—BRAF—thyroid cancer	1.18e-05	0.000268	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.16e-05	0.000263	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—thyroid cancer	1.16e-05	0.000262	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTEN—thyroid cancer	1.15e-05	0.000262	CbGpPWpGaD
Methotrexate—AOX1—Disease—BRAF—thyroid cancer	1.15e-05	0.000261	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.15e-05	0.000261	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CALCA—thyroid cancer	1.15e-05	0.000261	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.15e-05	0.00026	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—RXRA—thyroid cancer	1.14e-05	0.000259	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TPR—thyroid cancer	1.13e-05	0.000256	CbGpPWpGaD
Methotrexate—PGD—Disease—NRAS—thyroid cancer	1.13e-05	0.000255	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IFNA2—thyroid cancer	1.12e-05	0.000254	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.12e-05	0.000253	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PRKAR1A—thyroid cancer	1.11e-05	0.000252	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.11e-05	0.000252	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.09e-05	0.000247	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—SLC5A5—thyroid cancer	1.07e-05	0.000242	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—KRAS—thyroid cancer	1.07e-05	0.000242	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HPGD—thyroid cancer	1.07e-05	0.000241	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KRAS—thyroid cancer	1.06e-05	0.00024	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTEN—thyroid cancer	1.06e-05	0.000239	CbGpPWpGaD
Methotrexate—DHFR—Disease—BRAF—thyroid cancer	1.05e-05	0.000238	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDK1—thyroid cancer	1.04e-05	0.000236	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—RXRA—thyroid cancer	1.03e-05	0.000234	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.03e-05	0.000233	CbGpPWpGaD
Methotrexate—FPGS—Disease—AKT1—thyroid cancer	1.02e-05	0.000231	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PPARG—thyroid cancer	1.02e-05	0.00023	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AKT1—thyroid cancer	1e-05	0.000228	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1e-05	0.000228	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1e-05	0.000227	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PPARG—thyroid cancer	9.92e-06	0.000225	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.86e-06	0.000224	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—thyroid cancer	9.84e-06	0.000223	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.78e-06	0.000222	CbGpPWpGaD
Methotrexate—PGD—Disease—KRAS—thyroid cancer	9.69e-06	0.000219	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SLC5A5—thyroid cancer	9.63e-06	0.000218	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—thyroid cancer	9.54e-06	0.000216	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—thyroid cancer	9.49e-06	0.000215	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.38e-06	0.000213	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—thyroid cancer	9.32e-06	0.000211	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.29e-06	0.00021	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NRAS—thyroid cancer	9.25e-06	0.00021	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	9.15e-06	0.000207	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—thyroid cancer	9.08e-06	0.000206	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PPARG—thyroid cancer	9.03e-06	0.000205	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.02e-06	0.000204	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—thyroid cancer	9e-06	0.000204	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—RXRA—thyroid cancer	8.99e-06	0.000204	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.97e-06	0.000203	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.75e-06	0.000198	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—thyroid cancer	8.58e-06	0.000194	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.58e-06	0.000194	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AKT1—thyroid cancer	8.54e-06	0.000194	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—thyroid cancer	8.54e-06	0.000194	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—thyroid cancer	8.48e-06	0.000192	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC5A5—thyroid cancer	8.47e-06	0.000192	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRG1—thyroid cancer	8.35e-06	0.000189	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—thyroid cancer	8.32e-06	0.000189	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—thyroid cancer	8.23e-06	0.000187	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PPARG—thyroid cancer	8.22e-06	0.000186	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.22e-06	0.000186	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—thyroid cancer	8.13e-06	0.000184	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—RXRA—thyroid cancer	8.09e-06	0.000183	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—thyroid cancer	8.02e-06	0.000182	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—thyroid cancer	7.99e-06	0.000181	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—thyroid cancer	7.96e-06	0.00018	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—thyroid cancer	7.95e-06	0.00018	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—thyroid cancer	7.88e-06	0.000178	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.87e-06	0.000178	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—thyroid cancer	7.81e-06	0.000177	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—RXRA—thyroid cancer	7.69e-06	0.000174	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—thyroid cancer	7.5e-06	0.00017	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.48e-06	0.000169	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—thyroid cancer	7.42e-06	0.000168	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—thyroid cancer	7.39e-06	0.000168	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—thyroid cancer	7.27e-06	0.000165	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—thyroid cancer	7.25e-06	0.000164	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—thyroid cancer	7.23e-06	0.000164	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HIF1A—thyroid cancer	7.17e-06	0.000163	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—RXRA—thyroid cancer	7.12e-06	0.000161	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—thyroid cancer	7.1e-06	0.000161	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—thyroid cancer	7.08e-06	0.00016	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TPR—thyroid cancer	6.98e-06	0.000158	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—thyroid cancer	6.97e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.88e-06	0.000156	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PRKAR1A—thyroid cancer	6.87e-06	0.000156	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—thyroid cancer	6.81e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—thyroid cancer	6.77e-06	0.000153	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—thyroid cancer	6.66e-06	0.000151	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—thyroid cancer	6.6e-06	0.000149	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—thyroid cancer	6.52e-06	0.000148	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—thyroid cancer	6.47e-06	0.000147	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—thyroid cancer	6.39e-06	0.000145	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—thyroid cancer	6.24e-06	0.000141	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.23e-06	0.000141	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—thyroid cancer	6.2e-06	0.00014	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—thyroid cancer	6.19e-06	0.00014	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TPR—thyroid cancer	6.12e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.12e-06	0.000139	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—thyroid cancer	6.09e-06	0.000138	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PRKAR1A—thyroid cancer	6.02e-06	0.000136	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—thyroid cancer	5.98e-06	0.000135	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—thyroid cancer	5.94e-06	0.000135	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—thyroid cancer	5.68e-06	0.000129	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—thyroid cancer	5.68e-06	0.000129	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—thyroid cancer	5.68e-06	0.000129	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—thyroid cancer	5.64e-06	0.000128	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—thyroid cancer	5.43e-06	0.000123	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—thyroid cancer	5.4e-06	0.000122	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—thyroid cancer	5.31e-06	0.00012	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	5.25e-06	0.000119	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A5—thyroid cancer	5.23e-06	0.000118	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.17e-06	0.000117	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—thyroid cancer	5.13e-06	0.000116	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—thyroid cancer	5.11e-06	0.000116	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—thyroid cancer	4.96e-06	0.000112	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.9e-06	0.000111	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—thyroid cancer	4.85e-06	0.00011	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—thyroid cancer	4.83e-06	0.000109	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—thyroid cancer	4.8e-06	0.000109	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—thyroid cancer	4.8e-06	0.000109	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—thyroid cancer	4.68e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.58e-06	0.000104	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—thyroid cancer	4.5e-06	0.000102	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—thyroid cancer	4.47e-06	0.000101	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—thyroid cancer	4.47e-06	0.000101	CbGpPWpGaD
Methotrexate—ALB—Metabolism—RXRA—thyroid cancer	4.39e-06	9.95e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.27e-06	9.68e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—thyroid cancer	4.26e-06	9.66e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—thyroid cancer	4.19e-06	9.49e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—thyroid cancer	4.18e-06	9.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—thyroid cancer	4.02e-06	9.11e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—thyroid cancer	4.02e-06	9.1e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—thyroid cancer	3.92e-06	8.89e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—thyroid cancer	3.89e-06	8.82e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—RXRA—thyroid cancer	3.85e-06	8.72e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—thyroid cancer	3.82e-06	8.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—thyroid cancer	3.73e-06	8.46e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—thyroid cancer	3.6e-06	8.17e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—thyroid cancer	3.57e-06	8.09e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—thyroid cancer	3.54e-06	8.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—thyroid cancer	3.5e-06	7.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—thyroid cancer	3.33e-06	7.55e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—thyroid cancer	3.25e-06	7.37e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—thyroid cancer	3.21e-06	7.28e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—thyroid cancer	3.2e-06	7.26e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—thyroid cancer	3.11e-06	7.06e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—thyroid cancer	3.08e-06	6.99e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—thyroid cancer	3.06e-06	6.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—thyroid cancer	2.86e-06	6.47e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—thyroid cancer	2.77e-06	6.29e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—thyroid cancer	2.73e-06	6.19e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—thyroid cancer	2.7e-06	6.13e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—thyroid cancer	2.58e-06	5.84e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—thyroid cancer	2.43e-06	5.51e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—thyroid cancer	2.41e-06	5.46e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—thyroid cancer	2.24e-06	5.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—thyroid cancer	2.18e-06	4.94e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—thyroid cancer	2.02e-06	4.58e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—thyroid cancer	1.92e-06	4.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—thyroid cancer	1.91e-06	4.33e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—thyroid cancer	1.9e-06	4.31e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—thyroid cancer	1.78e-06	4.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—thyroid cancer	1.67e-06	3.78e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—thyroid cancer	1.1e-06	2.48e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—thyroid cancer	9.61e-07	2.18e-05	CbGpPWpGaD
